Ardelyx announced on October 28, 2024, the presentation of results from its IBS in America 2024 supplemental survey at the American College of Gastroenterology’s Annual Scientific Meeting. The survey, conducted in partnership with Health Union, aimed to understand the impact of irritable bowel syndrome with constipation (IBS-C) on patients' lives.
The survey revealed that 90% of IBS-C patients reported 'some' or 'significant' negative impact on their lives, extending beyond physical symptoms to mental and emotional health, sexual health, relationships, and independence. More than one-third of patients described their quality of life as 'poor' or 'fair.'
These findings underscore the substantial unmet need in the IBS-C patient community, reinforcing the importance of effective treatment options like IBSRELA. The data was presented in two poster presentations during the conference.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.